PURPOSE: To assess long-term functional outcome and survival among patients with meningioma World Health Organization (WHO) grade I. METHODS: Retrospective analysis of 205 patients after resection of WHO grade I intracranial meningioma from 1985 through 2003. Expected age- and sex-specific survival was calculated by applying Dutch life-table statistics to each patient for the individual duration of follow-up. Long-term functional outcome was assessed using a mailed questionnaire to the general practitioner. RESULTS: The mean duration of follow-up was 11.5 years. Survival at 5, 10, 15, and 20 years was 92%, 81%, 63%, and 53%, respectively, which is significantly lower than the expected survival (94%, 86%, 78%, and 66%, respectively). Survival was worse with higher age (P < .001). Survival among patients younger than 45 years and older than 65 years was comparable to the expected survival but significantly worse among patients aged 45-65 years. Analysis of the cause of death suggests an excess mortality associated with both brain tumor death and stroke (P = .07). Recurrence rates at 5, 10, and 15 years were 18%, 26%, and 32%, respectively. Higher Simpson grade (P < .001) and lower age (P = .02) were associated with a higher recurrence rate. In 29 patients (14%) receiving radiotherapy, the 5-year recurrence rate was 18% and the 5-year survival was only 58%. Long-term functioning (≥ 5 years after last treatment) could be assessed in 89 long-term survivors: 29 patients (33%) showed no deficits, and 60 (67%) showed at least 1 neurological symptom, of whom 24 (27%) were unable to perform normal daily activities. CONCLUSION: Long-term survival in WHO grade I meningioma is challenged in patients more than 45 years of age. Excess mortality seems to be associated with both tumor recurrence and stroke. The majority of patients have long-term neurological problems.
PURPOSE: To assess long-term functional outcome and survival among patients with meningioma World Health Organization (WHO) grade I. METHODS: Retrospective analysis of 205 patients after resection of WHO grade I intracranial meningioma from 1985 through 2003. Expected age- and sex-specific survival was calculated by applying Dutch life-table statistics to each patient for the individual duration of follow-up. Long-term functional outcome was assessed using a mailed questionnaire to the general practitioner. RESULTS: The mean duration of follow-up was 11.5 years. Survival at 5, 10, 15, and 20 years was 92%, 81%, 63%, and 53%, respectively, which is significantly lower than the expected survival (94%, 86%, 78%, and 66%, respectively). Survival was worse with higher age (P < .001). Survival among patients younger than 45 years and older than 65 years was comparable to the expected survival but significantly worse among patients aged 45-65 years. Analysis of the cause of death suggests an excess mortality associated with both brain tumor death and stroke (P = .07). Recurrence rates at 5, 10, and 15 years were 18%, 26%, and 32%, respectively. Higher Simpson grade (P < .001) and lower age (P = .02) were associated with a higher recurrence rate. In 29 patients (14%) receiving radiotherapy, the 5-year recurrence rate was 18% and the 5-year survival was only 58%. Long-term functioning (≥ 5 years after last treatment) could be assessed in 89 long-term survivors: 29 patients (33%) showed no deficits, and 60 (67%) showed at least 1 neurological symptom, of whom 24 (27%) were unable to perform normal daily activities. CONCLUSION: Long-term survival in WHO grade I meningioma is challenged in patients more than 45 years of age. Excess mortality seems to be associated with both tumor recurrence and stroke. The majority of patients have long-term neurological problems.
Authors: C Nutting; M Brada; L Brazil; A Sibtain; F Saran; C Westbury; A Moore; D G Thomas; D Traish; S Ashley Journal: J Neurosurg Date: 1999-05 Impact factor: 5.115
Authors: K S Condra; J M Buatti; W M Mendenhall; W A Friedman; R B Marcus; A L Rhoton Journal: Int J Radiat Oncol Biol Phys Date: 1997-09-01 Impact factor: 7.038
Authors: B J McCarthy; F G Davis; S Freels; T S Surawicz; D M Damek; J Grutsch; H R Menck; E R Laws Journal: J Neurosurg Date: 1998-05 Impact factor: 5.115
Authors: K A Peele; J S Kennerdell; J C Maroon; S Kalnicki; M Kazim; T Gardner; M Malton; T Goodglick; C Rosen Journal: Ophthalmology Date: 1996-11 Impact factor: 12.079
Authors: Victor M Lu; Anshit Goyal; Adrian Lee; Mark Jentoft; Alfredo Quinones-Hinojosa; Kaisorn L Chaichana Journal: J Neurooncol Date: 2018-12-01 Impact factor: 4.130
Authors: Stephen T Magill; Jonathan W Rick; William C Chen; David A Haase; David R Raleigh; Manish K Aghi; Philip V Theodosopoulos; Michael W McDermott Journal: World Neurosurg Date: 2018-04-04 Impact factor: 2.104
Authors: Adriana Olar; Khalida M Wani; Charmaine D Wilson; Gelareh Zadeh; Franco DeMonte; David T W Jones; Stefan M Pfister; Erik P Sulman; Kenneth D Aldape Journal: Acta Neuropathol Date: 2017-01-27 Impact factor: 17.088
Authors: Adomas Bunevicius; Andrius Radziunas; Sarunas Tamasauskas; Arimantas Tamasauskas; Edwards R Laws; Giorgio Iervasi; Robertas Bunevicius; Vytenis Deltuva Journal: J Neurooncol Date: 2018-02-19 Impact factor: 4.130
Authors: Georg Alexander Gihr; Diana Horvath-Rizea; Nikita Garnov; Patricia Kohlhof-Meinecke; Oliver Ganslandt; Hans Henkes; Hans Jonas Meyer; Karl-Titus Hoffmann; Alexey Surov; Stefan Schob Journal: Mol Imaging Biol Date: 2018-08 Impact factor: 3.488
Authors: Farshad Nassiri; Benjamin Price; Ameer Shehab; Karolyn Au; Michael D Cusimano; Michael D Jenkinson; Christine Jungk; Alireza Mansouri; Thomas Santarius; Suganth Suppiah; Ken X Teng; Gurvinder S Toor; Gelareh Zadeh; Tobias Walbert; Katharine J Drummond Journal: Neuro Oncol Date: 2019-01-14 Impact factor: 12.300